HCT‐FS‐Defined Frailty Is Associated With Lower Survival Across Diverse Hematologic Diagnoses After Allogeneic Transplantation
Аннотация
ABSTRACT Objectives To evaluate whether Hematopoietic Cell Transplantation Frailty Scale (HCT‐FS)‐defined frailty predicts overall survival (OS), nonrelapse mortality (NRM), and relapse across diverse hematologic diagnoses undergoing allogeneic hematopoietic cell transplantation (alloHCT), including nonmalignant disorders. Methods We conducted a multicenter retrospective cohort study of 992 adults undergoing alloHCT at 16 centers in Canada and Spain (2018–2023). Frailty was assessed at consultation using the HCT‐FS (fit, prefrail, frail). OS was estimated by Kaplan–Meier, competing‐risks methods by cumulative incidence. Multivariable models assessed associations with OS and NRM. Results Frailty was assessed across six diagnostic categories, including nonmalignant disorders (4.8%). At consultation, 32.1% were fit, 54.7% prefrail, and 13.2% frail. Increasing frailty was associated with progressively lower 2‐year OS (78.9%, 66.0%, 51.7%; p < 0.001) and higher 2‐year NRM (10.5%, 18.9%, 33.2%; p < 0.001; HR 1.77 [95% CI 1.21–2.60] prefrail and 3.65 [2.36–5.65] frail vs. fit), while 2‐year relapse incidence did not differ (19.0%, 23.5%, 22.3%; p = 0.229). Disease‐specific estimates were exploratory and limited by small subgroup sizes. Conclusions HCT‐FS‐defined frailty is associated with OS and NRM but not relapse in this multicenter alloHCT cohort. Larger disease‐specific studies are needed to establish its prognostic value in less represented indications.